By restoring the balance between proinflammatory and anti-inflammatory pathways, targeted modulation of SLAMF7 signaling offers a clinically viable strategy to disrupt the cycle of mucosal damage and inflammation in IBD patients. The gene discussed is SLAMF7; the disease is inflammatory bowel disease.